MAM
AZN icon

Morse Asset Management’s AstraZeneca AZN Stock Holding History

Morse Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,000
Closed -$197K – 418
2026
Q1 		$197K Buy
+1,000
New +$193K 0.04% 154
2025
Q2 		– Sell
-28
Closed -$4.12K – 366
2025
Q1 		$4.12K Buy
+28
New +$4.05K ﹤0.01% 283

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morse Asset Management's AZN Position: Q2 2026 in Review

Morse Asset Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,000 shares — an estimated $197K sold.

Morse Asset Management first reported a position in AZN in Q1 2025 and held it in 2 quarters. The position peaked at $197K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Morse Asset Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Morse Asset Management sold 1,000 AstraZeneca shares in Q2 2026, an estimated $197K.
  • Morse Asset Management first reported a position in AstraZeneca in Q1 2025 and held it in 2 quarters.
  • Morse Asset Management's AstraZeneca position peaked at $197K in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Morse Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.